$58.80
1.18% today
NYSE, May 15, 09:49 pm CET
ISIN
US26622P1075
Symbol
DOCS

Doximity Stock price

$59.50
+6.90 13.12% 1M
+7.46 14.34% 6M
+6.11 11.44% YTD
+35.99 153.08% 1Y
+26.51 80.36% 3Y
+6.50 12.26% 5Y
+6.50 12.26% 10Y
NYSE, Closing price Wed, May 14 2025
-0.93 1.54%
ISIN
US26622P1075
Symbol
DOCS

Key metrics

Market capitalization $11.16b
Enterprise Value $10.33b
P/E (TTM) P/E ratio 59.39
EV/FCF (TTM) EV/FCF 44.52
EV/Sales (TTM) EV/Sales 18.78
P/S ratio (TTM) P/S ratio 20.29
P/B ratio (TTM) P/B ratio 10.82
Revenue growth (TTM) Revenue growth 17.47%
Revenue (TTM) Revenue $550.17m
EBIT (operating result TTM) EBIT $223.97m
Free Cash Flow (TTM) Free Cash Flow $232.07m
Cash position $844.94m
EPS (TTM) EPS $1.00
P/E forward 59.36
P/S forward 19.73
EV/Sales forward 18.26
Short interest 6.97%
Show more

Is Doximity a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

Doximity Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Doximity forecast:

8x Buy
40%
12x Hold
60%

Analyst Opinions

20 Analysts have issued a Doximity forecast:

Buy
40%
Hold
60%

Financial data from Doximity

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
550 550
17% 17%
100%
- Direct Costs 54 54
4% 4%
10%
496 496
19% 19%
90%
- Selling and Administrative Expenses 173 173
10% 10%
32%
- Research and Development Expense 88 88
6% 6%
16%
234 234
33% 33%
43%
- Depreciation and Amortization 10 10
14% 14%
2%
EBIT (Operating Income) EBIT 224 224
37% 37%
41%
Net Profit 201 201
46% 46%
37%

In millions USD.

Don't miss a Thing! We will send you all news about Doximity directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Doximity Stock News

Neutral
Business Wire
about one hour ago
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. “We closed out fiscal 2025 on a high note, with record engagement, strong profits, and 20% annual revenue growth,” said Jeff Tangney, co-founder and CEO of Doximity. “Our newsfeed...
Neutral
GlobeNewsWire
about 7 hours ago
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Neutral
Seeking Alpha
14 days ago
Doximity is experiencing strong user engagement growth, driven by demand from medical prescribers and pharmaceutical marketers. Pharma marketing, Doximity's largest opportunity, is fueling sustained momentum alongside the early success of new platform tools. Integrated features like the client portal drive network effects and boost customer stickiness through real-time marketing insights.
More Doximity News

Company Profile

Doximity, Inc. operates an online platform for medical professionals. It's cloud-based software has the ability to enable the users to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. The company was founded by Konstantin Guericke, Nate Gross and Jeffrey A. Tangney in April 16, 2010 and is headquartered in San Francisco, CA.

Head office United States
CEO Jeffrey Tangney
Employees 827
Founded 2010
Website www.doximity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today